Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis

Background: Agents targeting the prostacyclin (PGI(2)) pathway are important in managing pulmonary arterial hypertension (PAH). No head-to-head clinical trials have compared outcomes between the 3 different PGI(2)-pathway drugs most commonly available in countries with advanced healthcare: oral sele...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Ci, Kunovszki, Peter, Beaudet, Amélie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2022
Materias:
Cardiovascular Conditions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178228/
https://www.ncbi.nlm.nih.gov/pubmed/35800882
http://dx.doi.org/10.36469/001c.35246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178228/
https://www.ncbi.nlm.nih.gov/pubmed/35800882
http://dx.doi.org/10.36469/001c.35246

Ejemplares similares